+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Remodulin

  • ID: 4775235
  • Report
  • October 2018
  • Region: Global
  • 15 pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
Drug Overview
Remodulin (United Therapeutics/Mochida) contains treprostinil, which is a prostaglandin analog that functions as a prostaglandin I2 receptor agonist. This leads to potent vasodilation of the pulmonary arteries and inhibition of platelet aggregation.

Analyst Outlook
Remodulin (treprostinil; United Therapeutics/Mochida) is a last-line treatment option for more severe patients. Despite Remodulin’s subcutaneous formulation reducing the risk of severe sepsis and thromboembolism associated with other intravenously administered prostacyclin analogs, injection site pain and site reactions remain a barrier to the drug’s uptake. Accordingly, United Therapeutics is developing three new formulations of Remodulin to overcome administration difficulties. The complexity of Remodulin’s administration and the introduction of a novel implantable pump developed in collaboration with Medtronic may provide a sustained market for Remodulin despite facing generic competition from 2018. Furthermore, United Therapeutics’ defensive acquisition of SteadyMed has enabled the company to circumvent potential competition from SteadyMed’s pipeline asset Trevyent, which is a PatchPump with treprostinil for subcutaneous treatment of pulmonary arterial hypertension (PAH).
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Remodulin : Pulmonary hypertension

LIST OF FIGURES
Figure 1: Remodulin for pulmonary hypertension – SWOT analysis
Figure 2: The authors drug assessment summary of Remodulin for pulmonary hypertension
Figure 3: The authors drug assessment summary of Remodulin for pulmonary hypertension
Figure 4: Remodulin sales for pulmonary hypertension across the US, Japan, France, Germany, and Italy, by country, 2016–25

LIST OF TABLES
Table 1: Remodulin drug profile
Table 2: Remodulin pivotal trial data in pulmonary hypertension
Table 3: Remodulin sales for pulmonary hypertension across the US, Japan, France, Germany, and Italy, by country ($m), 2016–25
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll